These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615 [TBL] [Abstract][Full Text] [Related]
4. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Blankenhorn DH; Alaupovic P; Wickham E; Chin HP; Azen SP Circulation; 1990 Feb; 81(2):470-6. PubMed ID: 2404631 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect. Blankenhorn DH; Selzer RH; Mack WJ; Crawford DW; Pogoda J; Lee PL; Shircore AM; Azen SP Circulation; 1992 Dec; 86(6):1701-9. PubMed ID: 1451241 [TBL] [Abstract][Full Text] [Related]
10. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. Hodis HN; Mack WJ; LaBree L; Cashin-Hemphill L; Sevanian A; Johnson R; Azen SP JAMA; 1995 Jun; 273(23):1849-54. PubMed ID: 7776501 [TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. Blankenhorn DH; Selzer RH; Crawford DW; Barth JD; Liu CR; Liu CH; Mack WJ; Alaupovic P Circulation; 1993 Jul; 88(1):20-8. PubMed ID: 8319334 [TBL] [Abstract][Full Text] [Related]
12. Serial quantitative coronary angiography and coronary events. Mack WJ; Xiang M; Selzer RH; Hodis HN Am Heart J; 2000 Jun; 139(6):993-9. PubMed ID: 10827379 [TBL] [Abstract][Full Text] [Related]
13. One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. Mack WJ; Selzer RH; Hodis HN; Erickson JK; Liu CR; Liu CH; Crawford DW; Blankenhorn DH Stroke; 1993 Dec; 24(12):1779-83. PubMed ID: 8248954 [TBL] [Abstract][Full Text] [Related]
14. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Blankenhorn DH; Johnson RL; Nessim SA; Azen SP; Sanmarco ME; Selzer RH Control Clin Trials; 1987 Dec; 8(4):356-87. PubMed ID: 3327654 [TBL] [Abstract][Full Text] [Related]
15. Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography. Mack WJ; LaBree L; Liu C; Selzer RH; Hodis HN Atherosclerosis; 2000 Jun; 150(2):371-9. PubMed ID: 10856529 [TBL] [Abstract][Full Text] [Related]
16. Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. Glueck CJ Ann Intern Med; 1982 Apr; 96(4):475-82. PubMed ID: 7039445 [TBL] [Abstract][Full Text] [Related]
17. The Cholesterol Lowering Atherosclerosis Study (CLAS): what it tells us about niacin/colestipol therapy. Hemphill LC J Clin Lipidol; 2015; 9(1):11-3. PubMed ID: 25670355 [No Abstract] [Full Text] [Related]
18. Reversibility of atherosclerosis--evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study. Hodis HN J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S25-31. PubMed ID: 8907211 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of two lipid-lowering treatments on quantitative coronary angiographic endpoints. Mack WJ; Xiang M; Shircore AM; Selzer RH; Hodis HN; Azen SP Cardiovasc Drugs Ther; 2000 Aug; 14(4):411-8. PubMed ID: 10999648 [TBL] [Abstract][Full Text] [Related]